Roberto Russo Selected Research

Phaseolus vulgaris alpha-amylase inhibitor (phaseolamin)

1/2019

Phaseolus vulgaris L. Extract: Alpha-Amylase Inhibition against Metabolic Syndrome in Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberto Russo Research Topics

Disease

21	Inflammation (Inflammations) 01/2022 - 01/2005
19	Pain (Aches) 12/2021 - 01/2005
10	Neuralgia (Stump Neuralgia) 03/2021 - 11/2005
9	Neoplasms (Cancer) 03/2022 - 11/2003
6	Hyperalgesia 05/2022 - 06/2009
5	Peripheral Nervous System Diseases (PNS Diseases) 05/2022 - 01/2017
3	Seizures (Absence Seizure) 01/2021 - 11/2016
3	Absence Epilepsy (Childhood Absence Epilepsy) 01/2020 - 06/2013
3	Chronic Pain 01/2020 - 01/2016
3	Hypertension (High Blood Pressure) 04/2018 - 10/2013
3	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 06/2012
3	Non-alcoholic Fatty Liver Disease 04/2016 - 01/2013
3	Insulin Resistance 04/2016 - 01/2013
3	Edema (Dropsy) 01/2012 - 01/2005
2	Bullous Pemphigoid (Pemphigoid) 06/2022 - 06/2020
2	Autistic Disorder (Autism) 01/2022 - 01/2018
2	Hemorrhage 01/2022 - 01/2018
2	Skin Diseases (Skin Disease) 12/2021 - 05/2016
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 09/2020
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 02/2020 - 04/2018
2	Chronic Renal Insufficiency 02/2020 - 07/2013
2	Epilepsy (Aura) 01/2020 - 11/2017
2	Facial Pain (Myofacial Pain) 11/2019 - 01/2018
2	Chronic Kidney Failure (Chronic Renal Failure) 06/2019 - 07/2013
2	Body Weight (Weight, Body) 01/2019 - 11/2013
2	Secondary Hyperparathyroidism 04/2018 - 10/2014
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 10/2014
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018 - 01/2017
2	Parkinson Disease (Parkinson's Disease) 01/2018 - 11/2016
2	Neuroblastoma 11/2016 - 10/2014
2	Vitamin D Deficiency 10/2014 - 07/2013
1	Atopic Dermatitis (Atopic Eczema) 06/2022
1	Anaphylaxis (Anaphylactic Shock) 05/2022
1	Hypersensitivity (Allergy) 05/2022
1	Dermatomyositis (Dermatopolymyositis) 03/2022
1	Carcinoma (Carcinomatosis) 03/2022
1	Hyperplasia 01/2022

Drug/Important Bio-Agent (IBA)

13	palmidrolIBA 01/2018 - 01/2005
9	Analgesics (Analgesic Drugs)IBA 12/2021 - 07/2007
6	PPAR alphaIBA 12/2009 - 01/2005
5	Formaldehyde (Formol)FDA Link 12/2021 - 12/2006
5	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2012
5	Biological ProductsIBA 01/2021 - 06/2005
5	Butyrates (Butyrate)IBA 01/2021 - 01/2013
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2016 - 06/2012
5	CarrageenanIBA 01/2012 - 01/2005
4	CannabinoidsIBA 08/2021 - 11/2016
4	Butyric Acid (Butanoic Acid)IBA 01/2020 - 01/2013
4	Glucose (Dextrose)FDA LinkGeneric 04/2016 - 01/2013
3	Paclitaxel (Taxol)FDA LinkGeneric 05/2022 - 01/2017
3	Therapeutic UsesIBA 03/2021 - 07/2013
3	LipidsIBA 01/2018 - 08/2005
3	anandamide (arachidonylethanolamide)IBA 01/2018 - 07/2007
3	EndocannabinoidsIBA 11/2017 - 07/2007
3	butyramideIBA 01/2017 - 01/2013
3	AmidesIBA 01/2013 - 01/2005
2	LigandsIBA 01/2022 - 10/2013
2	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2022 - 01/2018
2	SodiumIBA 02/2020 - 01/2017
2	Histone Deacetylase InhibitorsIBA 01/2020 - 01/2020
2	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 01/2020 - 07/2007
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2020 - 01/2020
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 01/2020
2	CholesterolIBA 01/2019 - 04/2016
2	Cholecalciferol (Vitamin D3)FDA Link 04/2018 - 10/2014
2	paricalcitol (Zemplar)FDA Link 04/2018 - 07/2013
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2018 - 10/2010
2	N-acylethanolaminesIBA 01/2018 - 12/2009
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 04/2016
2	ProdrugsIBA 01/2018 - 06/2009
2	Messenger RNA (mRNA)IBA 01/2018 - 04/2016
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2018 - 11/2005
2	Fatty Acids (Saturated Fatty Acids)IBA 11/2016 - 06/2013
2	Anticonvulsants (Antiepileptic Drugs)IBA 11/2016 - 06/2013
2	Antipsychotic Agents (Antipsychotics)IBA 07/2015 - 11/2013
2	Vitamin D FDA LinkGeneric 10/2014 - 07/2013
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 10/2013 - 12/2006
2	AcidsIBA 12/2009 - 07/2007
2	Pharmaceutical PreparationsIBA 06/2009 - 07/2007
2	NF-kappa B (NF-kB)IBA 06/2009 - 09/2007
2	GW 7647IBA 07/2007 - 12/2006
2	Ethanolamine (Colamine)IBA 08/2005 - 01/2005
2	Palmitic Acid (Hexadecanoic Acid)IBA 08/2005 - 01/2005
1	Immunoglobulin G (IgG)IBA 06/2022
1	dupilumabIBA 06/2022
1	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 06/2022
1	Monoclonal AntibodiesIBA 06/2022
1	Complement C5a (Complement 5a)IBA 05/2022
1	Antineoplastic Agents (Antineoplastics)IBA 05/2022
1	AntibodiesIBA 03/2022
1	lipoxin A4IBA 01/2022
1	Neuroprotective AgentsIBA 01/2022
1	Chemokine ReceptorsIBA 01/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 05/2022 - 11/2013
3	Oral Administration 10/2019 - 07/2007
3	Renal Dialysis (Hemodialysis) 06/2019 - 09/2012
3	Therapeutics 01/2017 - 10/2010
2	Continuous Ambulatory Peritoneal Dialysis (CAPD) 06/2019 - 11/2013
2	Peritoneal Dialysis 10/2014 - 11/2013